Table 1.
Patients characteristics, disease and treatment details
| Parameters | |
|---|---|
| Total study cohort N (%) | 58 (100) |
| Age N (%) | |
| Mean (years) , (Range) | 65.3 (41–81) |
| Sex N (%) | |
| Male | 43 (74.2%) |
| Female | 15 (25.8%) |
| Histology N (%) | |
| NSCLC | 44 (75.9%) |
| SCLC /NE | 13 (22.4%) |
| Sarcomatoid | 1 (1.7%) |
| Stage N (%) | |
| II | 3 (5.2%) |
| III | 53 (91.4%) |
| IV | 2 (3.4%) |
| Chemotherapy N (%) | |
| Cisplatin-Vinorelbine | 2 (3.4%) |
| Carboplatin-Paclitaxel | 29 (50%) |
| Etoposide- Cisplatin | 17 (29.3%) |
| Pemetraxed-Cisplatin | 2 (3.4%) |
| Cisplatin | 2 (3.4%) |
| Non | 6 (10.3%) |
| Radiation therapy | |
| Radiation Dose ; Mean (SD) | 59.45 Gray (4.8) |
| Total Number of Fractions ; Mean (SD) | 29 (3.5) |
| Number of Fractions In First Plan; Mean (SD) | 14.9 (6.8); range 2–25 |
| Duration of radiation treatment; Mean (SD) | 42.3 days (11.6) |
| Planning technique N (%) | |
| 3 Dimensional conformal | 12 (20.7%) |
| IMRT/VMAT | 34 (58.6%) |
| Hybrid | 12 (20.7%) |
| IGRT CBCT N (%) | |
| Daily | 45 (77.6%) |
| Weekly | 13 (22.4%) |
| Timing of second plan N (%) | |
| First third | 15 (26%) |
| Second third | 25 (43%) |
| Last third | 18 (31%) |
| Tumor Locations peribronchial (with atelectasis) N (%) | |
| Yes | 31 (53. 5%) |
| No | 27 (45.5%) |
| Changes In GTV Volume (More Than 20%) | |
| Decrease ; (Mean% From Initial GTV); Mean volume,±SD (ml)) | 35 (60.3%) ; (−40%; −124 ml,±SD 121) |
| Increase; (Mean % From Initial GTV); Mean volume ± SD (ml) | 8 (13.8%) ; (+89%;+65 ml,SD 50.8) |
| No Change ( ± 20%) (Mean % From Initial GTV); Mean volume ± SD (ml) | 15 (25.9) ; (−4% ; 20.8 ml,±SD 0.13) |
| Other Anatomical Changes Detected In CBCT N (%) | |
| Yes | 20 (34.5%) |
| No | 38 (65%) |
| Need to Improve Technique of Simulation N (%) | |
| Yes | 14 (24.2%) |
| No | 44 (75.8%) |
| Surgery after chemo-radiation N (%) | |
| Yes | 15 (25.9%) |
| No | 43 (74.1%) |
| Pathological Response (Total 15) N (%) | |
| Complete Response, no viable tumor cells | 8 (53.3%) |
| <10% Residual viable tumor cells | 5 (33.3%) |
| >10% Residual viable tumor cells | 2 (13.3%) |
CBCT, cone beam CT; GTV, gross tumor volume; IGRT, image guided radiation therapy; IMRT, intensity modulated radiation therapy; SCLC /NE, small cell lung cancer/neuroendocrine; SD, standard deviation; VMAT, volumetric modulated arc therapy.
Hybrid – combination of IMRT and 3D Conformal.